Juno Therapeutics, Inc. v. Kite Pharma, Inc., No. 20-1758 (Fed. Cir. Aug. 26, 2021)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Kite Pharma, Inc. appeals a final judgment of the United States District Court for the Central District of Cal- ifornia that (1) claims 3, 5, 9, and 11 of U.S. Patent No. 7,446,190 are not invalid for lack of written description or enablement, (2) the ’190 patent’s certificate of correction is not invalid, and (3) Juno Therapeutics, Inc., and Sloan Ket- tering Institute for Cancer Research (collectively, Juno) were entitled to $1,200,322,551.50 in damages. Juno Ther- apeutics, Inc. v. Kite Pharma, Inc., No. 2:17-cv-07639-PSG- KS, (C.D. Cal.